

NICE Technology Appraisals About Medicines: Formulary Adherence

Technology appraisal (TA) Titles are hyperlinks to full guidance	Date of TA Release	Availability of medicine for NHS patients with this medical condition, as indicated by NICE	Adherence of local formulary to NICE	
			Included on the Trust Formulary for this indication Yes OR No	Reason provided if "No"
2007-08				
Chronic asthma (in adults) - corticosteroids (TA138)	31/03/2008	Inhaled corticosteroids – the least costly suitable product is recommended when indicated. Inhaled corticosteroid with long-acting beta-2 agonist – a combination device is a recommended option; use the least costly. Separate inhalers may be suitable on an individual basis.	Yes	
Lymphoma (follicular non-Hodgkin's) - rituximab (TA137) Review of TA37	29/02/2008	Rituximab – a recommended option with chemotherapy to induce remission, or alone as maintenance therapy during remission. Monotherapy also an option for relapsed or refractory disease when other options exhausted.	Yes	
Mesothelioma - pemetrexed disodium (TA135)	31/01/2008	Pemetrexed – a recommended option for specified people with advanced or unresectable malignant pleural mesothelioma.	Yes	
Psoriasis - infliximab (TA134)	31/01/2008	Infliximab – a recommended option for severe plaque psoriasis if other treatments are unsuitable, unsuccessful or not tolerated.	Yes	
Chronic asthma (in children) - corticosteroids (TA131)	30/11/2007	Inhaled corticosteroids – when indicated, use the least costly suitable product. Inhaled corticosteroid with long-acting beta-2 agonist – when both indicated, a combination device may be used; use the least costly suitable option.	Yes	
Asthma (uncontrolled) - omalizumab (TA133)	30/11/2007	Omalizumab – recommended option for specified non-smokers with severe persistent allergic asthma, despite using other asthma medicines.	No	This medicine is not applicable to C&W
Hypercholesterolaemia - ezetimibe (TA132)	30/11/2007	Ezetimibe – a recommended option for heterozygous-familial and non-familial hypercholesterolaemia with a statin if cholesterol not low enough, or as monotherapy if a statin unsuitable.	Yes	
Multiple myeloma - bortezomib (TA129)	31/10/2007	Bortezomib – a recommended monotherapy for progressive multiple myeloma at first relapse after one prior therapy in people who have undergone, or are unsuitable for, bone marrow transplant.	Yes	

Rheumatoid arthritis - adalimumab, etanercept and infliximab (TA130) Partially updates TA36	31/10/2007	Adalimumab, etanercept, infliximab – recommended options for rheumatoid arthritis after trying methotrexate and another DMARD. Usually with methotrexate, but monotherapy if methotrexate unsuitable.	Yes	
Lung cancer (non-small-cell) - pemetrexed (TA124) (See TA181 for first line use)	31/08/2007	Pemetrexed – not recommended for locally advanced or metastatic non-small-cell lung cancer after prior chemotherapy.	Yes	
Multiple sclerosis - natalizumab (TA127)	31/08/2007	Natalizumab – a recommended option for rapidly evolving severe relapsing-remitting MS.	Yes	
Smoking cessation - varenicline (TA123)	31/07/2007	Varenicline – a recommended option for smokers who want to stop, normally as part of a cessation programme.	No	This medicine is not applicable to C&W
Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide (TA121)	30/06/2007	Carmustine implants – a recommended option for newly diagnosed high-grade glioma if more than 90% of the tumour has been removed. Temozolomide – a recommended option for newly diagnosed glioblastoma multiforme in specified circumstances.	No	This medicine is not applicable to C&W
Ischaemic stroke (acute) - alteplase (TA122)	30/06/2007	Alteplase – a recommended option for acute ischaemic stroke.	Yes	